Heron Therapeutics, Inc. /De/ financial data

Symbol
HRTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
4242 Campus Point Court, Suite 200, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
AP PHARMA INC /DE/ (to 1/7/2014), ADVANCED POLYMER SYSTEMS INC /DE/ (to 4/6/2001)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 235 % +4.79%
Quick Ratio 55.4 % -0.63%
Debt-to-equity -712 % +18.8%
Return On Equity 37.4 % -90.5%
Return On Assets -6.1 % +87.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 152M shares
Common Stock, Shares, Outstanding 152M shares +1.23%
Entity Public Float 394M USD +230%
Common Stock, Value, Issued 1.52M USD +1.2%
Weighted Average Number of Shares Outstanding, Basic 152M shares +10.4%
Weighted Average Number of Shares Outstanding, Diluted 152M shares +10.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16.7M USD -57.4%
Selling and Marketing Expense 47.1M USD -30.4%
General and Administrative Expense 53.4M USD -18.8%
Costs and Expenses 117M USD -32.1%
Operating Income (Loss) -11.5M USD +89.6%
Net Income (Loss) Attributable to Parent -13.6M USD +87.7%
Earnings Per Share, Basic -0.09 USD/shares +88.8%
Earnings Per Share, Diluted -0.09 USD/shares +88.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.8M USD -10%
Cash, Cash Equivalents, and Short-term Investments 59.3M USD -26.2%
Accounts Receivable, after Allowance for Credit Loss, Current 78.9M USD +31.2%
Inventory, Net 53.2M USD +26.2%
Assets, Current 209M USD +10.7%
Property, Plant and Equipment, Net 14.9M USD -26.3%
Operating Lease, Right-of-Use Asset 2.79M USD -48.8%
Other Assets, Noncurrent 6.48M USD -20.2%
Assets 233M USD +4.78%
Accounts Payable, Current 11.7M USD +261%
Employee-related Liabilities, Current 9.55M USD +3.58%
Liabilities, Current 91.5M USD +14.8%
Operating Lease, Liability, Noncurrent 522K USD -85.2%
Other Liabilities, Noncurrent 615K USD +155%
Liabilities 267M USD +4.02%
Accumulated Other Comprehensive Income (Loss), Net of Tax 13K USD 0%
Retained Earnings (Accumulated Deficit) -1.92B USD -0.71%
Stockholders' Equity Attributable to Parent -33.7M USD +0.95%
Liabilities and Equity 233M USD +4.78%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.52M USD +61.8%
Net Cash Provided by (Used in) Financing Activities -208K USD +67.3%
Net Cash Provided by (Used in) Investing Activities 1.28M USD -96.5%
Common Stock, Shares Authorized 400M shares +77.8%
Common Stock, Shares, Issued 152M shares +1.23%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.23M USD -170%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.8M USD -10%
Interest Paid, Excluding Capitalized Interest, Operating Activities 649K USD
Deferred Tax Assets, Valuation Allowance 419M USD -2.48%
Deferred Tax Assets, Gross 420M USD -2.63%
Operating Lease, Liability 3.04M USD -48.3%
Payments to Acquire Property, Plant, and Equipment 224K USD -78.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -13.6M USD +87.7%
Lessee, Operating Lease, Liability, to be Paid 3.14M USD -50.1%
Property, Plant and Equipment, Gross 32.7M USD -12.1%
Operating Lease, Liability, Current 3.04M USD -1.24%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.14M USD +3.56%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.14M USD -0.48%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 101K USD -75.7%
Deferred Tax Assets, Operating Loss Carryforwards 324M USD +0.99%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2.5M shares 0%
Unrecognized Tax Benefits 10.9M USD 0%
Additional Paid in Capital 1.88B USD +0.74%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 689K USD -4.04%
Share-based Payment Arrangement, Expense 13M USD -60.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%